Rowan University and Sentrimed®; A clinical stadium biochemical company that focused on the development of safer oncology treatments, it announced results today by a National Cancer Institute (NCI) funding a clinical trial rated by Masl® In patients with slab cell carcinoma (OSCC). The company’s product candidate, Masl, is a new therapeutic lectin that has been licensed from Rowan University. Results from this Human Phase 1 test, led by Dr. Gary Goldberg at the Rowan-Virtua Osteopathic Medicine School and Dr. Mahnaz FataAhzadeh from Rutgers School of Dentistry, recently published in The Journal of Cancer Research and Clinical Oncology And it has shown Masl’s potential to cope with the critical unfulfilled needs in the treatment of oral cancer.
Masl is a first in the category, a therapeutic oral treatment targeting Podoplanin (PDPN), a oncogenic transmembrane glycoprotein receptor expressed in malignant cells in more than 75% of patients with oral cancer. PDPN plays a key role in promoting the proliferation of tumor cells, migration, tax evasion and treatment resistance. With the targeting of PDPN, Masl can disrupt the basic oncogenic signaling pathways that lead to the development and mortality of cancer.
“The results of this study indicate that Masl can be developed to help treat OSCC damage,” said Dr. Gary Goldberg, who has conducted an innovative research on intracellular communication and her role in cancer development and is a founder and chief scientific. “The single oral dose of Masl used in this study did not cause side effects or side effects in any patients. In addition, Masl appeared to stimulate an anti -immune response to one of the three patients examined within 24 hours after dosage.
Ex vivo Studies that used tumor cells derived from this Phase 1 test have found that MASL steadily inhibits the viability and mobility of oral cancer and mobility in crop. In addition, studies with these cells also show that antibodies can target PDPN to selectively destroy human cancer cells from the mouth using photocopying near infrared (Nir-Pit). This study was supported by Rowan University, Rutgers University, NIH, Sentrimed and its New Jersey Medical School Partners and Tohoku University.
